You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid, Accurate, and Low-Cost Stool Clostridium difficile Genetic Test

    SBC: LENIMA FIELD DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Clostridium difficile (CD) is a bacterium causing diarrhea and other intestinal problems linked to 14,000 annual deaths in the US. CDI is an antibiotic-associated infection as well as a health-care-associated infection.Current CDI diagnosis relies on CD toxins enzyme immunoassay (EIA) together with antigen (GDH) EIA. Although stool toxin EIA is specific and rel ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells

    SBC: IMMUVEN, INC.            Topic: NCI

    Project Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Mucins in the Diagnosis and Prognosis of Pancreatic Diseases

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Due to its asymptomatic nature and lack of methods for early detection, gt 80% of pancreatic cancer (PC) patients present with an unresectable primary tumor with distant metastasis at the time of diagnosis. While the overall 5 year survival rate of pancreatic cancer is dismal, significantly better outcomes have been reported for smaller tumors detected at an e ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Genomic instability is a hallmark of cancer, yet is underdeveloped as a therapeutic target area The central goal of this program is to develop new cancer therapeutics that target genomic instability as a hallmark of cancer cells, bringing new, cancer-cell selective treatments to the clinical oncology market. Two key challenges in current cancer therapy are mini ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Microbial Surrogate Assay for Environmental PAH Exposure

    SBC: ARPHION LTD.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Arphion is a company established to develop noninvasive products that will be used to diagnose, prevent, and treat head and neck and other cancers. 41,000 people are diagnosed with head and neck cancer (HNC) every yearin the United States, with 8,000 deaths. Tens of millions of people in the US are at increased risk for HNC due to exposure to the polycyclic ary ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIGMS

    DESCRIPTION: While HIV/AIDS can be managed with antiretroviral drugs that block viral replication, these agents do not clear the virus and require life-long drug administration with associated risks of cumulative toxicity and drug resistance. Recently, wediscovered a completely new class of compounds that interfere with the HIV-1 virulence factor, Nef. This viral protein is critical to HIV-1 repli ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Cblb-based Drugs Against Sepsis and Inflammation

    SBC: CELL BIOLOGICS INC            Topic: NHLBI

    Abstract Septicemia poses a major health care challenge. Modern therapies requiring suppression of patients' immune systems, a growing numbers of elderly people in the population, and the emergence of drug-resistant bacteria, have increased the prevalenceand severity of the disease over the past few decades. Current treatments rely on drugs that do not significant reduce morbidity and mortali ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government